Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study - PubMed (original) (raw)
Clinical Trial
Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study
Shahin Merat et al. J Hepatol. 2003 Apr.
Abstract
Background/aims: A final step in the pathology of non-alcoholic steatohepatitis (NASH) is oxidative damage to hepatocytes. Probucol is a lipid-lowering agent with strong antioxidant properties. We designed a double-blind randomized controlled study to evaluate the effects of probucol in NASH.
Methods: Thirty cases of biopsy-proven NASH were included. Subjects were randomly allocated to either the treatment group or to the control group by a 2:1 ratio. The treatment group was given 500 mg of probucol daily for 6 months, and the control group, an identically appearing placebo.
Results: Twenty-seven cases completed the study. The mean aspartate transaminase (AST) and alanine transaminase (ALT) levels changed from 81.9 to 36.2 and 102.2 to 44.7 in the treatment group and from 57.6 to 49.6 and 96.8 to 96.2 in the control group, respectively. The decrease in ALT level in the treatment group as compared to the control group was significant at the P<0.005 level (95% confidence interval: 20.2-93.7 IU). Both AST and ALT levels dropped to normal in nine cases of the treatment group (50%) but none of the control group (P=0.01).
Conclusions: Probucol appears to be significantly effective in decreasing the ALT levels in patients with NASH.
Similar articles
- Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol.
Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R. Merat S, et al. Dig Dis Sci. 2008 Aug;53(8):2246-50. doi: 10.1007/s10620-007-0109-6. Epub 2007 Nov 30. Dig Dis Sci. 2008. PMID: 18049900 Clinical Trial. - Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study.
Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, Farahvash MJ, Ansari R, Sotoudehmanesh R, Khatibian M. Merat S, et al. J Clin Gastroenterol. 2003 Mar;36(3):266-8. doi: 10.1097/00004836-200303000-00015. J Clin Gastroenterol. 2003. PMID: 12590240 Clinical Trial. - Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study.
Chande N, Laidlaw M, Adams P, Marotta P. Chande N, et al. Dig Dis Sci. 2006 Jul;51(7):1183-9. doi: 10.1007/s10620-006-8030-y. Dig Dis Sci. 2006. PMID: 16944007 Clinical Trial. - Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Eslami L, et al. Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Cochrane Database Syst Rev. 2013. PMID: 24374462 Review. - Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Angelico F, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. doi: 10.1002/14651858.CD005166.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253544 Review.
Cited by
- Current status of therapy in nonalcoholic Fatty liver disease.
McNear S, Harrison SA. McNear S, et al. Therap Adv Gastroenterol. 2009 Jan;2(1):29-43. doi: 10.1177/1756283X08100327. Therap Adv Gastroenterol. 2009. PMID: 21180532 Free PMC article. - The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.
Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. Jalili R, et al. Adv Pharm Bull. 2020 Sep;10(4):542-555. doi: 10.34172/apb.2020.065. Epub 2020 Aug 9. Adv Pharm Bull. 2020. PMID: 33072533 Free PMC article. Review. - Pharmacological agents for nonalcoholic steatohepatitis.
Guillaume M, Ratziu V. Guillaume M, et al. Hepatol Int. 2013 Dec;7 Suppl 2:833-41. doi: 10.1007/s12072-013-9482-8. Epub 2013 Nov 19. Hepatol Int. 2013. PMID: 26202298 - Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol.
Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R. Merat S, et al. Dig Dis Sci. 2008 Aug;53(8):2246-50. doi: 10.1007/s10620-007-0109-6. Epub 2007 Nov 30. Dig Dis Sci. 2008. PMID: 18049900 Clinical Trial. - Nonalcoholic fatty liver disease in children living in the obeseogenic society.
Hesham A-Kader H. Hesham A-Kader H. World J Pediatr. 2009 Nov;5(4):245-54. doi: 10.1007/s12519-009-0048-8. Epub 2009 Nov 13. World J Pediatr. 2009. PMID: 19911138 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical